[Infographics] Darolutamide + ADT in mHSPC: rPFS, time to mCRPC, OS & QoL benefits

11 Nov 2026
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team
[Infographics] Darolutamide + ADT in mHSPC: rPFS, time to mCRPC, OS & QoL benefits

Darolutamide + ADT in patients with mHSPC provides a clinically significant delay in radiographic progression with minimal treatment burden.1

The clinically meaningful delays in pain progression and time to deterioration of overall well-being vs placebo + ADT support consideration of darolutamide + ADT as a SoC treatment option in patients with mHSPC.2

ARASEC provides further evidence for the efficacy and safety of darolutamide + ADT in mHSPC, reinforcing findings from ARANOTE.3

References:

  1. J Clin Oncol 2024;42:4271-4281.
  2. Lancet Oncol 2026;27:614-624.
  3. McKay R, et al, AUA 2026, presentation P2.
This special report is supported by an education grant from the industry. 

Resources

[Infographics] Darolutamide + ADT in mHSPC: rPFS, time to mCRPC, OS & QoL benefits [Infographics] Darolutamide + ADT in mHSPC: rPFS, time to mCRPC, OS & QoL benefits

[Infographics] Darolutamide + ADT in mHSPC: rPFS, time to mCRPC, OS & QoL benefits